Adenovirus-mediated transfer of the 39 kD receptor-associated protein increases fibrinolytic capacity

Kidney International

Volumn 60, Issue 1, 2001, Pages 117-125

  Goedde, Martin F ^a,b   Grimbergen, Jos M ^a,b   Toet, Karin H ^a,b   Sitter, Thomas ^a,b   Quax, Paul H ^a,b   Kooistra, Teake ^a,b  

^a TNO   (Netherlands)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Adhesion prevention; CAPD; Fibrin; Host defense; Mesothelial cells; Peritoneal cavity; Tissue type plasminogen activator

Indexed keywords

BETA GALACTOSIDASE; COMPLEMENTARY DNA; CYTOKINE; LIPOPROTEIN RECEPTOR; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR ASSOCIATED PROTEIN; RECEPTOR PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ADENOVIRUS; ARTICLE; CONTROLLED STUDY; FIBRINOLYSIS; GENE TRANSFER; HUMAN; HUMAN CELL; MESOTHELIUM CELL; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; VIRUS INFECTION; VIRUS RECOMBINANT;

EID: 0034959987     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.00778.x     Document Type: Article

References (32)

1. Ultrastructure and pathology of the peritoneum in peritoneal dialysis
2. The mesothelium: Its fibrinolytic properties
3. Peritoneal fibrinolytic activity and intra-abdominal adhesions
4. Role of imbalance of intracavity fibrin formation and removal in the pathogenesis of peritoneal lesions in CAPD
5. Evidence for the presence of chronic inflammation during peritoneal dialysis: Therapeutic implications
6. Reduced human peritoneal plasminogen activating activity: Possible mechanism of adhesion formation
7. Intraperitoneal coagulation and fibrinolysis during inflammation: In vivo and in vitro observations
8. Recombinant tissue plasminogen activator reduces adhesion formation in a rabbit uterine horn model
9. The effect of streptokinase on experimental intraperitoneal adhesion formation
10. Mesothelial cell-mediated gene therapy: Feasibility of an ex vivo strategy
11. Modulation of transgene expression in mesothelial cells by activation of an inducible promoter
12. The potential of gene therapy in the peritoneal cavity
13. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator
14. An endothelial cell growth factor from bovine hypothalamus: Identification and partial characterization
15. 2-macroglobulin receptor
16. Identification of domains on the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein
17. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist
18. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice
19. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway
20. Characterization and fibrinolytic properties of human omental tissue mesothelial cells: Comparison with endothelial cells
21. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
22. Modulation of procoagulant and fibrinolytic system components of mesothelial cells by inflammatory mediators
23. The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes
24. RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors
25. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist
26. Adhesion-related hospital readmissions after abdominal and pelvic surgery: A retrospective cohort study
27. Use of fibrinolytic agents in the prevention of postoperative adhesion formation
28. Kinetics of transperitoneal tissue-type plasminogen activator absorption
29. Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice
30. Mesothelial cell-mediated gene therapy: Feasibility of an ex vivo strategy
31. Systemic delivery of a recombinant protein by genetically modified mesothelial cells reseeded on the parietal peritoneal surface
32. Intraperitoneal injection of genetically modified, human mesothelial cells for systemic gene therapy